Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$1.71
$0.01(0.80%)
At close: 4:00 PM EDT
$1.71
$0.01(0.80%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous Close$1.26
Volume536.26K
Average Volume (3M)1.24M
Market Cap
$130.47M
Enterprise Value$72.05
Total Cash (Recent Filing)$34.82M
Total Debt (Recent Filing)$877.00K
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding72,483,850
10 Day Avg. Volume2,760,520
30 Day Avg. Volume1,237,609
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.80Price Target Upside297.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage limits mandatory financing costs and reduces balance-sheet risk while the company funds clinical development. This provides some financial flexibility compared with a highly indebted biotech, although it does not eliminate the need for future capital.
Narrowing LossesThe substantial reduction in losses indicates improving cost control and a more disciplined operating profile. If sustained, this trend could extend the company’s financing runway and reduce the capital required to advance its pipeline before potential revenue begins.
Proprietary Drug Discovery PlatformA proprietary covalent chemistry platform can support repeatable internal drug discovery across oncology and metabolic diseases. Its long-term value depends on clinical validation, but the platform gives Biomea a focused technology base rather than a single undifferentiated candidate.
Bears Say
No Commercial RevenueWithout approved products, Biomea lacks recurring customer revenue and remains dependent on successful clinical development before establishing a durable commercial model. Delays, failures, or regulatory setbacks could therefore postpone or prevent meaningful revenue generation.
Persistent Cash BurnSustained negative operating and free cash flow means the company must continue funding research and clinical programs through external capital or partnerships. This creates financing dependence and could constrain development priorities if capital markets or partnering opportunities weaken.
Shrinking Capital CushionThe sharp decline in equity reflects cumulative losses and leaves a thinner balance-sheet cushion to absorb clinical or operating setbacks. Combined with ongoing cash burn, it increases the likelihood that future funding could dilute existing shareholders or limit pipeline investment.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $130.47M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Nov 03, 2026 which is in 60 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Aug 05, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.103.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,483,850 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.80 (297.66% Upside)
$6.80 (297.66% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 53.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 132.5%
Last 30 Days ▲ 132.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biomea Fusion
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
BMEA Stock 12 Month Forecast
Average Price Target
$6.80
▲(297.66% Upside)
Technical Analysis
Ownership Overview
3.71% Insiders
11.19% Mutual Funds
4.75% Other Institutional Investors
76.11% Public Companies and
Individual Investors